New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 11, 2012
06:55 EDTSHPGY, SHPGY, SHPGY, INFI, INFI, INFI, AMGN, AMGN, AMGN, LXRX, LXRX, LXRX, ZGNX, ZGNX, ZGNX, EPCT, EPCT, EPCT, MRK, MRK, MRK, BIIB, BIIB, BIIB, AZN, AZN, AZN, GSK, GSK, GSK, CELG, CELG, CELG, KFY, KFY, KFYElsevier Business Intelligence to host a conference
Pharmaceutical Strategic Outlook: Biopharma Strategic Dealmaking Conference is being held in New York on April 11-13 with pre-conference workshops being held on April 11 and the conference starting on April 12 at 8 am.
News For KFY;CELG;GSK;AZN;BIIB;MRK;EPCT;ZGNX;LXRX;AMGN;INFI;SHPGY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 14, 2015
09:22 EDTMRK, AZNLeerink pharma/biotech analysts hold an analyst/industry conference call
Subscribe for More Information
07:44 EDTAMGNInternational Headache Society to hold a conference
17th Congress of the International Headache Society is being held in Valencia, Spain on May 14-17.
05:52 EDTAZNMizuho expects CAR T stocks to be volatile after ASCO abstract
Subscribe for More Information
May 13, 2015
18:33 EDTMRKMerck to present new Keytruda data on 10 types of cancer at 2015 ASCO meeting
Subscribe for More Information
17:42 EDTCELGCelgene announces over 55 blood, solid tumor cancer study presentations at ASCO
Subscribe for More Information
17:25 EDTINFIInfinity Pharmaceuticals to present new data for duvelisib at ASCO
Subscribe for More Information
17:24 EDTAZNAstraZeneca to update progress with immuno-oncology pipeline at ASCO
AstraZeneca and MedImmune, the company’s global biologics research and development arm, will demonstrate rapid progress with their combination-focused oncology pipeline at the American Society of Clinical Oncology, or ASCO, Annual Meeting, May 29-June 2. 61 scientific abstracts will be presented at the meeting, reinforcing the significant progress in immuno-oncology through combination therapies and innovative companion diagnostics.
17:17 EDTAMGNAmgen to present key results in solid tumor, hematologic malignancy treatments
Subscribe for More Information
13:12 EDTMRKSen. Sanders urges VA to break patents on Gilead hepatitis C drugs
Subscribe for More Information
11:38 EDTGSKGlaxoSmithKline downgraded to Neutral from Buy at UBS
Subscribe for More Information
07:32 EDTBIIBBiogen names Matt Griffiths as CIO
Subscribe for More Information
07:07 EDTGSKGSK, Emergent BioSolutions, Oxford initiate Prime Boost study of Ebola vaccine
A new phase 1 study has begun at the University of Oxford that will investigate the use of a modified vaccinia Ankara, or MVA, Ebola Zaire vaccine candidate, or MVA EBOZ, as a prime-boost to GlaxoSmithKline's (GSK) Chimp Adenovirus type 3, or ChAd3, Ebola vaccine candidate. The study, being conducted by the clinical research group of Professor Adrian Hill of the Jenner Institute, has received regulatory approval to begin from the United Kingdom's Medicines and Healthcare Products Regulatory Agency, or MHRA. The phase 1 study has a planned enrollment of 38 volunteers of which 6 will receive MVA EBOZ only while the other 32 will receive ChAd3-EBO-Z prime followed by MVA EBOZ boost. Emergent BioSolutions (EBS) manufactured the supply of MVA EBOZ to be used in this phase 1 study, which is being conducted in the U.K. with support from the Wellcome Trust and the U.K. Department for International Development.
May 12, 2015
13:13 EDTMRKExpert says Norway biosimilar case an 'outlier,' CT Financial News reports
Subscribe for More Information
07:33 EDTCELGAlliqua announces licensing agreement with Celgene
Subscribe for More Information
06:09 EDTMRKThreshold announces Merck receives FDA Fast Track designation for evofosfamide
Subscribe for More Information
06:02 EDTGSKGSK CEO cites 'poor choices' in rivals' M&A deals, Financial Times reports
Subscribe for More Information
May 11, 2015
16:12 EDTZGNXZogenix sees Q2-Q4 R&D expenses $25M-$28M
Subscribe for More Information
16:11 EDTZGNXZogenix reports Q1 EPS (15c), consensus (13c)
Subscribe for More Information
15:54 EDTGSKGlaxo CEO defends strategy, warns of risks of chasing higher prices, FT says
GlaxoSmithKline (GSK) CEO Andrew Witty defends the company's shift in focus from high-priced prescription drugs to higher volume, but lower priced, products, warning that chasing ever-higher prices risks undermining the industry and may create "its own tension that leads to some kind of change,” reported Financial Times, citing an interview. Witty acknowledges the company's asset swap with Novartis (NVS) opens the door to a potential break up, but argues there are benefits to keeping pharmaceuticals, vaccines and consumer goods together and there would be “no logic” in a split at this early time after the Novartis deal, the report added. Reference Link
05:58 EDTGSKUNC, GlaxoSmithKline create dedicated HIV Cure center
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use